Anaptysbio Stock Today
| ANAB Stock | USD 16.73 0.11 0.65% |
PerformanceWeak
| Odds Of DistressLow
|
AnaptysBio is trading at 16.73 as of the 17th of March 2025, a 0.65 percent decrease since the beginning of the trading day. The stock's open price was 16.84. AnaptysBio has only a 6 % chance of going through financial distress over the next few years but had a somewhat weak performance during the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of January 2017 | Category Healthcare | Classification Health Care |
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 30.67 M outstanding shares of which 9.31 M shares are presently shorted by private and institutional investors with about 6.91 trading days to cover. More on AnaptysBio
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
AnaptysBio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAnaptysBio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AnaptysBio's financial leverage. It provides some insight into what part of AnaptysBio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AnaptysBio (ANAB) is traded on NASDAQ Exchange in USA. It is located in 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801 and employs 136 people. AnaptysBio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 513.06 M. AnaptysBio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.67 M outstanding shares of which 9.31 M shares are presently shorted by private and institutional investors with about 6.91 trading days to cover.
AnaptysBio currently holds about 442.15 M in cash with (135.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66.
Check AnaptysBio Probability Of Bankruptcy
Ownership AllocationThe majority of AnaptysBio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AnaptysBio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AnaptysBio. Please pay attention to any change in the institutional holdings of AnaptysBio as this could imply that something significant has changed or is about to change at the company.
Check AnaptysBio Ownership Details
AnaptysBio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| First Light Asset Management, Llc | 2024-12-31 | 868.9 K | |
| Palo Alto Investors, Llc | 2024-12-31 | 844 K | |
| Sanofi | 2024-12-31 | 821.9 K | |
| Geode Capital Management, Llc | 2024-12-31 | 486.6 K | |
| Woodline Partners Lp | 2024-12-31 | 485.1 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 419.1 K | |
| Soleus Capital Management, L.p. | 2024-12-31 | 414 K | |
| 5am Venture Management, Llc | 2024-12-31 | 357.7 K | |
| Franklin Resources Inc | 2024-12-31 | 354.4 K | |
| Ecor1 Capital, Llc | 2024-12-31 | 7.9 M | |
| Fmr Inc | 2024-12-31 | 3 M |
AnaptysBio Historical Income Statement
AnaptysBio Stock Against Markets
AnaptysBio Corporate Management
| Martin Dahl | Senior Research | Profile | |
| Monique Silva | Senior Affairs | Profile | |
| James MD | Advisor | Profile | |
| Beth Mueller | Senior Resources | Profile | |
| Priya Raina | Senior Operations | Profile | |
| FAAD MBA | Chief Officer | Profile | |
| Daniel Faga | Interim Director | Profile |
Already Invested in AnaptysBio?
The danger of trading AnaptysBio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AnaptysBio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AnaptysBio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AnaptysBio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.12) | Revenue Per Share | Quarterly Revenue Growth 3.788 | Return On Assets | Return On Equity |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.